The Annual General Meeting in Active Biotech AB (publ) (“Active Biotech” or the “Company”) held on May 20, 2026, resolved to carry out a reverse share split 1:100, whereby hundred (100) shares are consolidated into one (1) share. The Annual General Meeting authorized the Board of Directors to determine the record date for the reverse share split. Pursuant to the authorization, the Board of Directors has today resolved that the record date for the reverse share split shall be June 4, 2026.
Timetable for the reverse share split
| June 2, 2026 | Last day of trading in Active Biotech’s shares prior to the reverse share split. |
| June 3, 2026 | First day of trading in Active Biotech’s shares following the reverse share split. First day of trading with the new ISIN code. |
| June 4, 2026 | Record date for the reverse share split. |
Shareholders do not need to take any action in connection with the reverse share split.
As a result of the reverse share split, the shares in Active Biotech will change ISIN code. As of June 3, 2026, the shares will be traded under the new ISIN code SE0029278555.
The reverse share split will be carried out automatically via Euroclear Sweden AB. If a shareholder’s holding is not divisible by hundred (100), the excess shares will pass to the Company on the record date. Excess shares will, without unnecessary delay, be sold at the Company’s expense via Mangold Fondkommission AB, following which the affected shareholders will automatically receive their proportionate share of the sale proceeds.
Following the reverse share split, the number of shares in Active Biotech will amount to 26,360,671 shares.
This is information that Active Biotech is obliged to make public pursuant to the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out below, at 08.30 CEST on May 28, 2026.